Answers are grounded in this paper and cite their sources.
Combination therapy with enfortumab vedotin, a Nectin-4-targeted antibody-drug conjugate, and pembrolizumab, an anti-PD1 antibody, recently supplanted platinum-based chemotherapy as standard first-line systemic therapy for patients with muscle-invasive or metastatic urothelial cancer. A composite biomarker integrating membranous Nectin-4 expression and NECTIN4 gene amplification is predictive of response to enfortumab vedotin.
No takes yet. Share an insight, caveat, or question.
Rodrigues et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: